The most effective treatment for weight gain is through exercise, diet, and behavioral modifications. If these methods alone do not result in at least 5 percent weight loss in weight loss, then weight loss medication can be considered an option to treat weight management.1,2 Patients with an index of body mass (BMI) of more than 30 kg/m2 or greater than 27 kg/m2 who have danger factors (e.g., diabetes, diabetic, or high blood pressure) could be suitable for weight loss medication to be used alongside other primary treatment therapies.1,2
There are currently six weight loss medicines available that have been FDA-approved for long-term use. This means they can be used as long as they are effective for weight loss or maintenance and aren’t producing adverse reactions. We’ve listed each drug below that covers all you need to know about.
Orlistat (Xenical(r) or Alli(r))
Buy phentermine Online Used to control weight loss in conjunction with a calorie-reduced diet and reduce the chance of weight gain after the loss.
Action mechanism: It is an intestinal lipase inhibitor that blocks the breakdown of dietary triglycerides in monoglycerides and fatty acids. A calorie deficit can be observed because triglycerides not digested aren’t consumed. Reduces absorption of fats from food by 30 percent.
Contraindications: Cholestasis, fat malabsorption, pregnancies
Affects adverse: abdominal discomfort, flatulence, steatorrhea, liver failure, headache, kidney stones
Dosing: 120 mg oral thrice a day at or within 1 hour of every meal containing fats. The recommended dosage for over-the-counter use is 60 mg orally three times a day. This is during or within 1 hour after each fat-rich meal.
Important note: A multivitamin is required (including fat-soluble vitamins D, A, E, and K). Consume at least 2 hours before or after taking Orlistat.
Phentermine/Topiramate Extended Release (Qsymia(r))
Action mechanism: Imitates amphetamines’ pharmacologic effects. An anorectic that helps boost the release of hypothalamic catecholamines. This can result in a reduction in appetite and a decrease in food consumption. Some believe Topiramate decreases the need and improves satiety.
Contraindications: Pregnancy, hyperthyroidism and breastfeeding, glaucoma, and concurrent use of monoamine oxide inhibitors (MAOI) or within 14 days after stopping MAOI. Doses higher than the maintenance dose are not advised for patients with severe or moderate renal or mild liver impairment.
Affects adverse: Paresthesia, constipation, dysgeusia, blurred vision, dizziness, insomnia: kidney stones, a higher heart rate, and mental disorders.
Dosing: The starting dosage of phentermine is 3.75 mg/topiramate 23,5 mg oral every day for 14 consecutive days. The dose for maintenance is Phentermine hydrochloride 7.5 mg/Topiramate at least daily.
Important note: If % weight loss of 3% is not seen within 12 weeks of 7.5 mg/46 mg, stop or increase the dosage. Do not take medication when the weight loss of 5% is not seen within 12 weeks of the maximum daily dose, 15 mg/92 mg.
Naltrexone Sustained Release (SR)/Bupropion SR (Contrave(r))
The mechanism of action Naltrexone acts as an antagonist of opioids, and Buying Phentermine Online can be described as an aminoketone-based antidepressant that has moderate inhibitory effects on neuronal reuptake and release of dopamine and norepinephrine, which aids in regulating the intake of food, as per non-clinical research. The precise neurochemical factors which cause weight loss aren’t entirely known.
Contraindications: Use of chronic opioids, opiate agonists, or MAOIs; acute withdrawal from opiates; or abrupt stoppage of benzodiazepines, alcohol barbiturates, or antiepileptic medications. Eating disorders, seizures. Pregnant women with uncontrolled hypertension or using other bupropion-containing drugs.
Adverse effects: Hypertension, increased pulse rate, sweating, nausea, abdominal pain, constipation, vomiting, cholecystitis, diarrhea, xerostomia, headache, dizziness, insomnia, anxiety, seizures, Depression, Irritation, Depression.
Liraglutide 3.0 mg (Saxenda(r))
Action mechanism: A acylated human glucagon-like protein-1 (GLP-1) receptor antagonist, which increases levels of insulin release in the face of high blood glucose levels and decreases glucagon secretion in a manner that is dependent on glucose, and delays gastric emptying. This reduces the rate at which blood glucose after a meal enters circulation. GLP-1 regulates appetite and calorie consumption. Loss of weight could be due to a decrease in consumption of energy.
Contraindications: Breastfeeding, pregnancy, and medullary thyroid cancer or endocrine neoplasia type 2 history.
Affects adverse: Hypertension, increased blood pressure, skin rash, nausea, hypoglycemia, indigestion, abdominal pain, headache, constipation, diarrhea, fatigue, dizziness, pancreatitis, and cholelithiasis. Sinusitis, renal failure, Angioedema
Dosing: Initial dosage is 0.6 mg/day subcutaneously for a week. The dose increases by 0.6 mg/day until a maintenance dose of 3 mg per day subcutaneously is reached.
Important note: Stop taking the medication when 4% weight loss is not seen in the week of 16.
Semaglutide (Wegovy(r))
The mechanism of action is the GLP-1 receptor antagonist that interacts with and activates the GLP-1 receptor. This is the physiological regulator of appetite.
Contraindications The following are contraindications: History of medullary thyroid cancer or multiple endocrine benign syndromes type 2 pregnancy, or the intention of becoming pregnant within two months.
Affects adverse: Increased heart rate, Depression, nausea, diarrhea, dizziness, constipation, vomiting, flatulence, gastroesophageal respiratory illness, headache, pancreatitis, hypoglycemia, cholelithiasis, renal impairment, Diabetic retinopathy.
Dosing: Start with 0.25 mg every day on the same days for four weeks. After four weeks, increase the dosage until the dose that maintains 2.4 mg is attained. Single-dose pre-filled pens purchased in 0.25 mg, 0.5 mg, 1, 1.7 mg, and 2.4 mg.
Important note: If patients cannot take 2.4 mg of maintenance dose may temporarily lower to 1.7 mg dosage. After four weeks, increase the amount to the maintenance dose of 2.4 mg. When a person cannot take maintenance doses, stop taking the medication.
Setmelanotide (IMCIVREE(r))
Buy Phentermine for managing the weight gain of both pediatric and adult patients who are six years old and over who suffer from Obesity caused by rare genetic disorders like proopiomelanocortin (POMC) Proprotein convertase subtilisin/kexin Type 1 (PCSK1) and leptin receptor (LEPR) deficiencies that are confirmed through genetics tests.
The mechanism of action is Melanocortin 4 (MC4) receptor agonist that restores diminished MC4 receptor pathway. The MC4 receptors of the brain are linked to the control of hunger, satiety, and energy expenditure.
The contraindications are Obesity due to suspected PCSK1, POMC, or LEPR deficiency POMC PCSK1, LEPR, or POMC variants that are classified as benign or likely to be gentle or likely harmless, as well as Obesity that is not correlated in these rare genetic diseases.
Adverse effects: Depression, hyperpigmentation of the skin, nausea, diarrhea, headache, stomach pain, fatigue, nausea, vomiting, penile erections, and upper respiratory tract infections.
Dosing: For adults and children aged 12 and above, The recommended dose for children of 2 mg (0.2 milliliters) daily for two weeks. If it is tolerated, increase up to 3 mg (0.3 milliliters) every day. For children aged between 6 and 12, the initial dosage will be 1 mg (0.1 milliliters) daily for two weeks. You can be increased by 2 mg (0.2 milliliters) every day if tolerated. If the higher dose is intolerant, the amount is reduced.
Important note: Stop taking the medication if a patient hasn’t lost at minimum 5% of their body weight (or 5%) of their baseline BMI (for patients with a continued expansion possibility) in the first 12-16 weeks of treatment.
